Senzime AB Sees Q1 Dip but Growth Intact

Senzime AB ((SE:SEZI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Senzime AB’s latest earnings call struck an overall optimistic tone despite a softer first quarter on headline numbers. Management highlighted strong sensor growth, a rising base of recurring revenue and improving underlying margins while framing the Q1 slowdown as a temporary outlier tied to delayed U.S. orders, currency and tariff headwinds, and regulatory timing in Asia rather than demand weakness.

Sensor Momentum and Recurring Revenue Scale

Sensor sales surged around 40% in constant currencies, with rolling 12‑month sensor volumes up roughly 27%. The company crossed the milestone of more than one million patients monitored, underscoring the growing importance of disposables as the primary revenue driver and a key lever for recurring, high‑margin income.

U.S. Disposables and As‑a‑Service Acceleration

In the U.S., disposables expanded about 55% in local currency and total U.S. business grew roughly 11% despite FX pressure. Senzime shipped 246 TetraGraphs in the U.S., with 120 monitors placed under the new TetraGraph‑as‑a‑Service model, which shortens sales cycles and is expected to enhance long‑term sensor profitability.

Installed Base Growth and Pediatric Expansion

Globally, cumulative TetraGraph shipments topped approximately 5,500 units, with 376 monitors delivered in Q1 versus 443 a year earlier. The company reported notable pediatric traction, delivering 65 TetraGraphs to pediatric operating rooms and tripling pediatric sensor unit volumes during the quarter.

Underlying Margin Strength Despite Headwinds

Underlying gross margin improved to about 69.2%, although reported gross margin came in at 63.1% after FX and tariff impacts. Management has begun lifting prices, including around a 5% increase in average selling prices in the U.S., and expects further margin gains from pricing power and operating scale.

Tighter Cost Control and Improved Cash Dynamics

Operating expenses fell about 5% year on year and 17.5% versus the prior quarter, reflecting tighter cost discipline. Operating cash flow improved by roughly 33%, EBITDA and net earnings also moved in the right direction, and with SEK 55.3 million in cash plus undrawn credit Senzime sees a solid funding runway.

Guideline Tailwinds and New Digital Offerings

The publication of a new European pediatric guideline recommending quantitative, preferably EMG‑based, monitoring provides a clinical tailwind for adoption. Senzime also launched TetraCom, an EHR connectivity solution enabling integration with major systems and monitoring partners, creating fresh opportunities for software‑driven services and recurring revenue.

Major Customer Wins and Pipeline Support

The company secured meaningful U.S. wins including Ivy League hospitals, a large integrated delivery network expansion with an estimated SEK 6 million annual run rate and extensions at major children’s and Florida hospitals. Management now counts around 250 U.S. hospitals as customers and points to a robust pipeline as justification for keeping full‑year targets intact.

Q1 Labeled an Outlier Amid Delayed Deals

Management characterized Q1 as a one‑off soft quarter, with delayed U.S. monitor purchases pushing revenue into later periods. Reported U.S. sales declined about 5% in Swedish krona, equivalent to roughly SEK 2.5 million, but many of those deals were said to be sliding into the second quarter rather than lost.

FX and Tariffs Masking Operational Progress

A strong SEK versus a weak USD and U.S. tariffs weighed heavily on reported results, with currency effects cited at around SEK 2.5 million and tariffs totaling roughly SEK 5 million. These external factors temporarily dragged reported gross margin well below the underlying level, and management is pursuing reimbursement while acknowledging ongoing FX uncertainty.

Lower Quarterly Shipments Versus a Strong Comparator

Monitor shipments slipped to 376 units from 443 in the prior‑year quarter, a decrease of around 15%. The company emphasized that last year’s quarter benefited from a wave of upgrades and demo units, and that the overall installed base continues to expand alongside rising sensor volumes.

Asian Regulatory Timing and Volume Shifts

Japan and South Korea saw timing and regulatory delays that pushed some shipments and sensor volumes into future periods. In particular, pending approval in South Korea is holding back near‑term growth, contributing to a regional phase shift rather than a structural demand problem.

Cash Flow Path Hinges on Execution

Despite a 33% improvement, operating cash flow remains negative, underscoring that Senzime must execute on sales growth and cost control to reach its goals. The company’s plan relies on continued margin expansion, working‑capital efficiencies and potential tariff recoveries to achieve its target of turning cash‑flow positive by the fourth quarter.

Hospital Adoption and Sales‑Cycle Risks

Management acknowledged that sales into hospitals and large IDNs remain susceptible to long procurement cycles and internal contracting delays. Clinician adoption and full penetration of large systems will require ongoing engagement, guideline alignment and time, leaving execution risk on the path to broader commercialization.

Guidance and Outlook Anchored in Growth and Margins

Senzime reiterated its 2026 targets, including sales growth “in line with previous years,” reflecting an historic five‑year compound annual growth rate near 60%. The company expects a rebound in Q2, continued margin expansion from the 69.2% underlying level and flat to lower operating expenses, all supporting its ambition to be cash‑flow positive by the fourth quarter of 2026.

The earnings call painted a picture of a company with strong underlying momentum but exposed to external and execution risks. Investors are likely to focus on whether delayed U.S. deals close as expected, FX and tariff pressures ease and Asian approvals come through, as these factors will determine whether Senzime can convert its growing installed base and sensor demand into sustained cash‑generating growth.